Competition for kids' medical devices kicks off; OrthoSpace starts pivotal trial;

@FierceMedDev: Natera bags $180M in IPO to ramp up R&D. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI last week: FDA warns that Maquet's anesthesia system could lead to a fatal stop in ventilation. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FierceDiagnostics: BG Medicine gets FDA blessing for automated chronic heart failure test. Article | Follow @EmilyWFierce

> The Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Health System is accepting proposals for novel medical devices that meet an unmet medical need for children. It will award two top prized of $50,000 in October. More

> OrthoSpace has started a 184-patient pivotal trial for its InSpace biodegradable balloon system to conventional repair or partial repair for the treatment of full thickness massive rotator cuff tears. More

> Dialysis provider Renal Ventures Management has partnered with Authentidate Holding ($ADAT) to gain remote monitoring for its kidney failure patients, which is expected to roll-out this quarter. More

Biotech News

@FierceBiotech: Who should make this year's Fierce 15? Nominate the most promising private biotechs. Nomination form | Follow @FierceBiotech

@JohnCFierce: Aimmune joins the biotech IPO scrum in search of $115M--plus a roundup of biotech IPO news. More | Follow @JohnCFierce

@DamianFierce: $AGN is paying $MRK $250M to become the roughly 127th company developing CGRP blockers for migraine. Release | Follow @DamianFierce

> Esperion's PCSK9 spoiler clears another FDA roadblock as it heads to Phase III. Story

> Essex Woodlands raises $360M for new life sciences fund. Item

> Aimmune joins the biotech IPO scrum in search of $115M. Article

Pharma News

@FiercePharma: Horizon targets Depomed's pain portfolio with $3B hostile bid. News | Follow @FiercePharma

@EricPFierce: Don't miss our July 8 Twitter chat on sustained release with BASF expert Thorsten Cech. Details are here | Follow @EricPFierce

@CarlyHFierce: ICYMI from FiercePharmaMarketing: Expecting payer pushback, Vertex to field new CF med Orkambi at $259K. Report | Follow @CarlyHFierce

> AstraZeneca and Cephalon pony up $50M+ to settle Medicaid pricing claims. News

> Doctor faces sentencing for 'over the top' cancer drug dosing. Item

> Mylan didn't disclose director's ties to HQ land deal: WSJ. Report

Drug Delivery News

> Natural bioluminescence provides inside look at drug-cell interactions. Story

> FDA to review modified-release version of Pfizer's Xeljanz for rheumatoid arthritis. More

> Novo ends microneedle patch diabetes partnership with Zosano. Article

> UCSB team tackles aggressive kidney disease by hitching a ride into cysts. Story

> China's Wuzhou says it will take 10% stake in oral insulin specialist Oramed for $52M. Report

Pharma Manufacturing News

> India's Lupin gets Russian production site in deal for Biocom. More

> Boehringer Ingelheim unloads vet plant in Iowa to contract manufacturer. Story

> FDA warns consumers to check any generic Valium bought online; it may be dangerous. Article

> Actavis yanks more than half a million boxes of birth control pills for packaging faux pas. News

> Europe says Israel and Brazil can ship APIs without having to certify them. Item

Pharma Asia News

> China's Guangxi Wuzhou builds stake in Israel's Oramed with diabetes in focus. More

> Shanghai, Shenzhen IPO halts won't spoil the China healthcare party. Story

> More trouble for India's CROs as Quest Life Sciences hauled up by WHO in HIV trial. Report

> Indian court upholds BMS Sprycel patent, but list of challengers grows. News

> Alibaba Health plans wider online sales push in China as competition heats up. Article

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.